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ABSTRACT
Background: Hepatitis C still remain a serious problem in Indonesia lead to increasing prevalence , major 
morbidity and mortality. Liver biopsy is gold standar, invasive procedure for liver fibrosis staging for treatment 
monitoring and fibrosis regression. Fibrosis-4 (FIB-4) score has been proposed as a non-invasive, easy, 
inexpensive as alternative indirect marker for the assessment of liver fibrosis in chronic hepatitis C (CHC).
Method: Analytical cross sectional study was conducted among 54 patients with CHC from 2012 -2017 in 
Saiful Anwar Hospital Malang. Subjects were examined for complete blood count, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), anti hepatitis C virus (anti HCV), hepatitis C virus ribonucleic acid 
(HCV RNA), genotype, and performed liver biopsy. Statistical analysis was performed using Spearman test and 
statistical significant was assumed when p < 0,05.
Results: Fifty four (54) patients were fulfilled the selection criteria from total 67 patients. 29 (53%) males, 
and 25 (47%) were females. The characteristic were 33 (61%) genotype 1, 12 (22%) genotype 2, 5 (9%) genotype 
3, and undetermined 3 (6%); with means of HCV RNA titer 2,57 x 106, AST 79 ± 44 IU/L, ALT 77 ± 48 IU/L 
platelet 160.000/mm3. Distribution of Metavir F1 10 (19%) , Metavir F2 31(57%), Metavir F3 6(11%), and 
Metavir F4 7 (13%). Median of FIB-4 score as Metavir F1 1,88;Metavir F2 3,24; Metavir F3 5,36; Metavir F4 
4,36. There was positive correlation between FIB-4 score and Metavir score (r = 0.38; p = 0,01). 
Conclusion: This study indicate that there was significant correlation between FIB-4 score and Metavir 
score in CHC patients.
Keywords: Fibrosis-4 (FIB-4), Metavir, chronic hepatitis C, fibrosis 
ABSTRAK 
Latar belakang: Hepatitis C merupakan masalah yang serius di Indonesia, dengan peningkatan angka 
prevalensi, morbiditas dan mortalitas. Biopsi hati saat ini masih merupakan standar baku untuk menilai derajat 
fibrosis, monitoring pengobatan dan regresi fibrosis pada pasien hepatitis. Diperlukan marker penilaian derajat 
fibrosis pada pasien hepatitis C kronis yang bersifat non invasif, mudah , murah seperti penilaian dengan skor 
Fibrosis-4 (FIB-4).
Metode: Studi analisis potong lintang pada 54 pasien hepatitis C Kronis yang memenuhi kriteria inklusi 
dari tahun 2012- 2017 di RS Saiful Anwar Malang. Pasien diperiksa darah lengkap aspartate aminotransferase 
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(AST), alanine aminotransferase (ALT), anti hepatitis C virus (anti HCV), hepatitis C virus ribonucleic acid 
(HCV RNA), genotipe dan dilakukan biopsi hati. Uji Statistik menggunakan korelasi Spearman dan bermakna 
signifikan dengan p < 0,05.
Hasil: Lima puluh empat (54) pasien memenuhi kriteria inklusi dari total 67 pasien, 29 (53%) laki-laki , 
dan 25 (47%) perempuan. Karakteristik data didapatkan 33 (61%) genotipe 1, 12(22%) genotipe 2, 5 (9%) 
genotipe 3, and undetermined 3 (6%); dengan rata-rata HCV RNA titer 2,57 x 106 , AST 79 ± 44 IU/L, ALT 77 
± 48 IU/L platelet 160.000/mm3. Distribusi of Metavir F1 10 (19%), Metavir F2 31 (57%), Metafir F3 6 (11%), 
and Metavir F4 7 (13%). Median FIB-4 Sesuai Metavir F1 1,88; Metavir F2 3,24; Metavir F3 5,36; Metavir 
F4 4,36. Terdapat korelasi positif antara Skor FIB-4 dan Skor Metavir (r = 0.38; p = 0,01). 
Simpulan: studi ini menyimpulkan adanya korelasi positif antara skor FIB-4 dan skor Metavir. 
Kata kunci: fibrosis-4 (FIB-4), Metavir, hepatitis C kronis, fibrosis, derajat fibrosis
INTRODUCTION
Chronic hepatitis C virus (HCV) infection is a 
major public health problem, affecting an estimated 
more than 100 million with 3-4 million new cases 
each year. Patients infected with Hepatitis C virus 
have different clinical outcomes, ranging from acute 
resolving hepatitis to chronic liver disease including 
liver cirrhosis or hepatocelluler carcinoma.1,2 
Liver fibrosis is a common pathological process 
of all chronic liver diseases, regardless of it causes, 
resulting from excessive accumulation of extracellular 
matrix. Estimating the degree of fibrosis has plays a 
very important role to monitor treatment or fibrosis 
regression.3 The gold standard for fibrosis assessment 
is a liver biopsy. Because this procedure is invasive 
and has many limitations, including the risk of patient 
injury and error sampling, so non-invasive serum 
marker for liver fibrosis are being considered.4,5
FIB-4 score with components were age, aspartate 
aminotransferse (AST) serum level, alanine 
aminotransferase (ALT) serum level and platelet count 
has been proposed as a non-invasive, easy, cheap as 
alternative indirect markers for the assessment of liver 
fibrosis in chronic hepatitis C (CHC). The aim of this 
study was to know the correlation between FIB-4 score 
to metavir score in CHC patients.4,5,6
METHOD
This study was conducted in Division of 
Gastroenterology and Hepatology, Department of 
Internal Medicine, Saiful Anwar Hospital, in the period 
between 2012-2017. A total of 67 patients with chronic 
HCV infection were enrolled in the study (Figure 1). 
Inclusion criteria: (1) Patients diagnosed with 
CHC; (2) Agreed to perform liver biopsy. Exclusion 
criteria: (1) Patients with hepatocelluler carcinoma; 
(2) Patients with diabetes mellitus; (3) Patients 
with HBV-HIV co-infections; (4) Any other liver 
diseases; (5) Thrombocytopenia not related to portal 
hypertension. All patients were subjected to the 
following: history taking, through clinical examination, 
laboratory investigations including: complete blood 
count, liver function test, Hepatitis C virus antibodies 
using ELISA technique, HCV RNA and genotype of 
hepatitis C virus, and performed liver biopsy guided 
ultrasonography.
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Liver fibrosis is a common pathological process of all chronic liver diseases, regardless of 
it causes, resulting from excessive accumulation of extracellular matrix. Estimating the degree of 
fibrosis has plays a very important role to monitor treatment or fibrosis regression.3 The gold 
standard for fibrosis assessment is a liver biopsy. Because this procedure is invasive and has many 
limitations, including the risk of patient injury and error sampling, so non-invasive serum marker 
for liver fibrosis are being considered.4,5 
FIB-4 score with components were age, aspartate aminotransferse (AST) serum level, 
alanine aminotransferase (ALT) serum level and platelet count has been proposed as a non-
invasive, easy, cheap as alternative indirect markers for the assessment of liver fibrosis in chronic 
hepatitis C (CHC). The aim of this study was to k ow t e correlation betwe n FIB-4 score to 
metavir score in CHC patients.4,5,6
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with chronic HCV infection were enrolled in the study (Figure 1).
 
 
 
 
 
 
 
Figure 1. Flow chart 
 
Inclusion criteria: (1) Patients diagnosed with CHC; (2) Agreed to perform liver biopsy. 
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Metavir score based on biopsy result 
Data Analysis
Figure 1. Flow chart
METAVIR scoring system was used to assess 
the necroinflamatory grades of activity and stage of 
fibrosis. There are 4 stage of fibrosis (F): (1) F0: no 
fibrosis; (2) F1: portal fibrosis without septa; (3) F2: 
portal fibrosis with rare septa; (4) F3: numerous septa 
without cirrhosis; (5) F4: cirrhosis. The FIB-4 score 
was calculated according to the formula: 
FIB4 = Age (Years) x AST (IU/L)
Platelet count (109/L)x√ALT(UL/L)
 
Results are expressed as absolute frequencies (%), 
means ± standard deviations, and medians (minimum 
– maximum). Correlation between FIB-4 and fibrosis 
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stages was estimated by spearman correlation indexes. 
And p < 0.05 was considered as statistically significant. 
RESULTS 
Diagnostic model for liver fibrosis with non- 
invasive methods, has been published. Fifty-four 
patients fulfilled the selection criteria, Mean ages 
in these study was 58 ± 11 years old, Demographic 
and laboratory characteristics of these patients are 
summarized in table 1. 29 (53%) males , and 25 
(47%) were females. The characteristic were 33 (61%) 
genotype 1,12 (22%) genotype 2, 5 (9%) genotype 3, 
and undetermined 3 (6%); with means of HCV RNA 
titer 2,57 x 106 , AST 79 ± 44 IU/L, ALT 77 ± 48 IU/L 
platelet 160.000/mm3. Distribution of Metavir F1 10 
(19%), Metavir F2 31(57%), Metavir F3 6(11%), and 
Metavir F4 7 (13%). 
Table 1. Distribution of demographics characteristics and 
laboratory results
Characteristic Chronic hepatitis C   (n = 54)
Age 58.76 ± 11.69 (mean ±SD)
Gender
Male
Female
29 (53%)
25 (47%)
Genotype
1
2
3
4
Undetermined
33(61%)
12 (22%)
5 (9%)
1 (2%)
3 (6%)
Aspartate aminotransferase (AST) 
(IU/L)
79.09 ± 44.37 (Mean ±SD)
Alanine aminotransferase (ALT) 
(IU/L)
77.48 ± 50.68 (Mean ±SD)
Platelets(/mm3) 160.000 (Mean)
Hepatitis C virus ribonucleic acid 
(HCV RNA)
2.57 x 106 (Mean)
Metavir 
F0
F1
F2
F3
F4
0 (0%)
10 (19%)
31 (57%)
6 (11%)
7 (13%)
DISCUSSION
 Previous study by Farenci et al showed that FIB4 
index, provides a valuable, non-invasive measure of 
fibrosis and can be used to predict virologic response 
in patients treated with ribavirin in chronic hepatitis 
C patients. The distribution of metavir in F1 (male 
: female = 6:4), F2 (male : female = 14 : 17 and F3 
(male : female = 3 : 3) were equal in both gender but 
in contrary in F4 the highest prevalence was male 
(male : female = 6: 1) (Table 2).7 It was also shown 
that male patients were more likely to suffer from 
advanced fibrosis at a than female patients, which is 
not surprising given that male patients generally tend 
to have more severe liver diseases of most etiologies 
compared with females. In general, men are more 
likely to die from chronic liver disease and cirrhosis 
than are women.8 This phenomenon may be explained 
by the protective effect of female sex hormones on the 
progression of hepatic fibrosis.
Various potential mechanisms include the effect of 
sex hormones on oxidative and metabolic pathways, 
differential gene transcription in response to injury in 
women compared with men, and sex differences in 
immune regulation.8 Women clear acute hepatitis C 
virus (HCV) infection at a higher rate than do men.9 
Estrogen may have a protective role against fibrosis 
in viral hepatitis by inhibiting stellate cells, which are 
responsible for fibrogenesis in the liver.10
Table 2. Distribution of gender according to fibrosis stage
Metavir Males Females Total
F1 6 4 10
F2 14 17 31
F3 3 3 6
F4 6 1 7
From all patients, the highest prevalence is 
genotype 1. Its equal with study by Niu (2016) and 
Sievert (2011) about epidemiology Hepatitis C in Asia 
and Australia that said, distribution of genotype, mostly 
is genotype 1.11
Fib-4 score, we found increasing number of median 
equal with inceasing fibrosis degree of Metavir score, 
but we found it decrease in F4, although it still relate   
7 
 
 
Figure 1. Histogram of median and mean FIB-4 score to metavir score 
Spearman test was done to identify correlation between FIB-4 score and fibrosis degree 
with metavir in CHC patient, the result was positive correlation with eventhough its weak (r = 
0,38), with significant p value  p = 0.01 (p < 0.05). Platelets count decrease and AST leves increase 
with the progression of liver fibrosis. Platelet generation diminished secondary to a decreased 
production of thrombopoeitin by hepatocytes.12 Also, platelets are sequestred and destructed in the 
spleen as liver fibrosis advances and portal hypertension develops.13 As to AST, ongoing liver 
injury increases its release from mitochondria, and fibrosis decreases its clearance. 
Our study have several limitations, includes small sample size, so the data distribution were 
abnormal.. In summary, in our CHC patients, the FIB-4 score can be a useful as non-invasive 
methods for liver fibrosis and cirrhosis prediction, especially in limited sources, when liver biopsy 
and fibroscan facility were unavailable and contraindicated. 
CONCLUSION 
This study indicate that there was significant correlation between FIB-4 score and Metavir 
score in CHC patients. 
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Figure 1. Histogram of median and mean fibrosis-4 (FIB-4) 
score to metavir score
with severe fibrosis, as previous study that mention 
FIB-4 > 3.25 equal with severe fibrosis (F3-F4). 
Spearman test was done to identify correlation 
between FIB-4 score and fibrosis degree with metavir 
in CHC patient, the result was positive correlation with 
eventhough its weak (r = 0,38), with significant p = 
0.01 (  < 0.05). Platelets count decrease and AST leves 
increase with the pr gression of liver fibro is. Platelet 
gen r tion diminished secondary to a decre sed 
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production of thrombopoeitin by hepatocytes.12 Also, 
platelets are sequestred and destructed in the spleen 
as liver fibrosis advances and portal hypertension 
develops.13 As to AST, ongoing liver injury increases 
its release from mitochondria, and fibrosis decreases 
its clearance.
Our study have several limitations, includes small 
sample size, so the data distribution were abnormal. In 
summary, in our CHC patients, the FIB-4 score can be 
a useful as non-invasive methods for liver fibrosis and 
cirrhosis prediction, especially in limited sources, when 
liver biopsy and fibroscan facility were unavailable 
and contraindicated.
CONCLUSION
This study indicate that there was significant 
correlation between FIB-4 score and Metavir score in 
CHC patients. 
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